Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Brenda J. Gehrke"'
Autor:
Richard Pazdur, R. Angelo de Claro, Brenda J. Gehrke, Jonathon Vallejo, Olanrewaju O. Okusanya, Lori A. Ehrlich, Justin Earp, Eliford Kitabi, Michael L. Manning, Haiyan Chen, Sriram Subramaniam, Kelly J. Norsworthy, Nina Kim
Supplementary Figure from FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37f9e927b0f02dd17bba71a4f750e28e
https://doi.org/10.1158/1078-0432.22486850
https://doi.org/10.1158/1078-0432.22486850
Autor:
Richard Pazdur, Ann T. Farrell, Qing Zhou, Ping Zhao, Pengfei Song, Deborah Schmiel, Tiffany K. Ricks, Nitin Mehrotra, Susan Kirshner, Robert C. Kane, Candace Gomez-Broughton, Brenda J. Gehrke, Haw-Jyh Chiu, Reyes Candau-Chacon, Carolyn L. Yancey, Albert Deisseroth, Chia-Wen Ko, Donna Przepiorka
Preferred Terms included in grouped terms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04eb5dd9d2864438c9fd3c493117694a
https://doi.org/10.1158/1078-0432.22457625.v1
https://doi.org/10.1158/1078-0432.22457625.v1
Autor:
Richard Pazdur, R. Angelo de Claro, Brenda J. Gehrke, Jonathon Vallejo, Olanrewaju O. Okusanya, Lori A. Ehrlich, Justin Earp, Eliford Kitabi, Michael L. Manning, Haiyan Chen, Sriram Subramaniam, Kelly J. Norsworthy, Nina Kim
Supplementary Table from FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e6646e8ffd93f37274a5c4f534616d9
https://doi.org/10.1158/1078-0432.22486838
https://doi.org/10.1158/1078-0432.22486838
Autor:
Richard Pazdur, R. Angelo de Claro, Brenda J. Gehrke, Jonathon Vallejo, Olanrewaju O. Okusanya, Lori A. Ehrlich, Justin Earp, Eliford Kitabi, Michael L. Manning, Haiyan Chen, Sriram Subramaniam, Kelly J. Norsworthy, Nina Kim
On July 7, 2020, the Food and Drug Administration approved Inqovi (Otsuka Pharmaceutical Co.), an oral fixed-dose combination tablet comprising 35 mg decitabine, a hypomethylating agent, and 100 mg cedazuridine, a cytidine deaminase inhibitor (abbrev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b2657fe9db7acdd8a1b08385f0f4c14
https://doi.org/10.1158/1078-0432.c.6532403.v1
https://doi.org/10.1158/1078-0432.c.6532403.v1
Autor:
Nina Kim, Kelly J. Norsworthy, Sriram Subramaniam, Haiyan Chen, Michael L. Manning, Eliford Kitabi, Justin Earp, Lori A. Ehrlich, Olanrewaju O. Okusanya, Jonathon Vallejo, Brenda J. Gehrke, R. Angelo de Claro, Richard Pazdur
Publikováno v:
Clin Cancer Res
On July 7, 2020, the Food and Drug Administration approved Inqovi (Otsuka Pharmaceutical Co.), an oral fixed-dose combination tablet comprising 35 mg decitabine, a hypomethylating agent, and 100 mg cedazuridine, a cytidine deaminase inhibitor (abbrev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89cb8f049331b0d3b0c1fa1e112223a3
https://europepmc.org/articles/PMC9378483/
https://europepmc.org/articles/PMC9378483/
Autor:
Emily Y. Jen, Xin Wang, Meng Li, Hongshan Li, Shwu-Luan Lee, Nina Ni, Donna Przepiorka, Jonathon Vallejo, Ruby Leong, Lian Ma, Brenda J. Gehrke, Sherita McLamore, Marc R. Theoret, R. Angelo de Claro
Publikováno v:
Clin Cancer Res
On September 1, 2020, the FDA granted approval for oral azacitidine (Onureg, CC-486) for continued treatment of adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a15eb96636e21c767fb00fe11f8bc52
https://europepmc.org/articles/PMC9288471/
https://europepmc.org/articles/PMC9288471/
Publikováno v:
Learning and Motivation. 38:44-55
The purpose of the present experiment was to determine whether repeated cocaine exposure differentially affects sucrose-reinforced operant responding in rats raised in an enriched condition (EC) or an isolated condition (IC). Specifically, the perfor
Autor:
Nitin Mehrotra, Ping Zhao, Tiffany K. Ricks, Candace Gomez-Broughton, Carolyn L. Yancey, Donna Przepiorka, Chia-Wen Ko, Pengfei Song, Robert C. Kane, Richard Pazdur, Deborah Schmiel, Albert Deisseroth, Qing Zhou, Brenda J. Gehrke, Ann T. Farrell, Susan L. Kirshner, Reyes Candau-Chacon, Haw-Jyh Chiu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 21(18)
On December 3, 2014, the FDA granted accelerated approval of blinatumomab (Blincyto; Amgen, Inc.) for treatment of Philadelphia chromosome–negative relapsed or refractory precursor B-cell acute lymphoblastic leukemia (R/R ALL). Blinatumomab is a re
Autor:
Liang Zhao, Nitin Mehrotra, Albert Deisseroth, Lei Nie, Chia-Wen Ko, Ann T. Farrell, Richard Pazdur, Jeanne Fourie Zirkelbach, Christopher M. Sheth, Haleh Saber, Brenda J. Gehrke, Pedro L. Del Valle, Julie Bullock, Robert Justice
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 21(5)
On April 22, 2014, the FDA granted full approval to siltuximab (SYLVANT for injection; Janssen Biotech, Inc.), a chimeric human-mouse monoclonal antibody to IL6, for the treatment of patients with multicentric Castleman disease (MCD) who are human im
Publikováno v:
Behavioural Pharmacology. 17:499-508
The current study examined whether environmental enrichment alters the effects of monoamine-depleting doses of methamphetamine on subsequent methamphetamine-induced hyperactivity and conditioned place preference. Rats were raised in either an enriche